Sintica Biotech is a biopharmaceutical company focused on the development of innovative treatments to address high unmet medical needs in dermato-oncological diseases.

Sintica has focused its first-line activities on melanoma, a serious form of skin cancer that begins in cells known as melanocytes. Melanoma is the most invasive skin cancer with the highest risk of death. Sintica has developed a peptidomimetic, SNT001, addressing an unprecedented pharmacological target to induce apoptosis in melanoma cells.